The immunosuppressive potential of misoprostol--efficacy and variability.

Clin Immunol

Department of Internal Medicine-Nephrology, University Hospital Charité, Campus Mitte, Humboldt-University, Berlin, Germany.

Published: December 2003

Existing evidence on the immunosuppressive efficacy of prostaglandin E (PGE) and its analogues in vivo is conflicting. We investigated the effect of misoprostol, an orally available PGE1 analogue, on T-cell proliferation, Th cell-derived cytokine production, and phagocytosis in healthy volunteers. All participants (n=20) received increasing doses of misoprostol (0-400 microg). Blood was drawn before and after intake. Misoprostol intake caused a time- and dose-dependent reduction of anti-CD3-stimulated cell proliferation. Whereas the synthesis of Th1 cytokines (IL-2 and IFN-gamma) was dose-dependently reduced, IL-10 expression was increased at lower misoprostol doses. Concerning IL-4 expression, we observed an increased IL-4 production in males, but a decreased IL-4 production in females. Misoprostol intake also reduced phagocytosis activity in a dose-dependent manner. At least in part our results explain the immunosuppressive effects of misoprostol observed in vivo. The considerable interindividual variability as well as gender-specific differences seem to account for the variability of clinical study results.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2003.08.009DOI Listing

Publication Analysis

Top Keywords

misoprostol intake
8
il-4 production
8
misoprostol
6
immunosuppressive potential
4
potential misoprostol--efficacy
4
misoprostol--efficacy variability
4
variability existing
4
existing evidence
4
evidence immunosuppressive
4
immunosuppressive efficacy
4

Similar Publications

Background: Optimising management of second-trimester medical abortion is important, as complications increase with gestational age. We aimed to compare a 24-h interval with a 48-h interval between mifepristone intake and misoprostol administration in in-hospital, second-trimester medical abortion for effectiveness and acceptability.

Methods: This open-label, randomised, controlled, non-inferiority trial was conducted at nine hospitals in India, Sweden, Thailand, and Viet Nam among adults undergoing medical abortion for a singleton viable pregnancy at a gestation of between 9 weeks and 20 weeks.

View Article and Find Full Text PDF

A pregnant woman was brought to the emergency department looking starved and neglected. She was diagnosed with sepsis and started on intravenous antibiotics. She was also disoriented and hypernatremic.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the effectiveness of misoprostol before hysteroscopy in women who have never given birth (nulliparous).
  • A total of 13 studies involving 1,528 participants were analyzed, comparing misoprostol to various alternatives including placebo and other medications.
  • Results indicated mixed outcomes on cervical dilation and pain levels, with a significant reduction in time for cervical dilatation (p=0.03), but no strong evidence for improved ease of dilation or reduced preoperative pain.
View Article and Find Full Text PDF

Home use of mifepristone for medical abortion: a systematic review.

BMJ Sex Reprod Health

October 2024

Swedish Agency for Health Technology Assessment and Assessment of Social Services, Stockholm, Sweden.

Article Synopsis
  • Many countries allow women to self-administer misoprostol for medical abortions at home, while mifepristone is often required to be taken in a clinic, leading to questions about the implications of home administration.
  • This systematic review analyzed whether at-home intake of mifepristone affects abortion effectiveness, safety, and women's satisfaction compared to clinic intake.
  • The results showed no significant differences in abortion effectiveness, compliance, or complications between home and clinic settings, with most women preferring to take mifepristone at home.
View Article and Find Full Text PDF

Introduction: The 2022 Massachusetts Shield Law protects telemedicine providers who care for abortion seekers in other states from criminal, civil, and licensure penalties. In this article we explore the characteristics of patients of The Massachusetts Medication Abortion Access Project (The MAP).

Methods: The MAP is an asynchronous telemedicine service that offers mifepristone/misoprostol to abortion seekers in all 50 states who are at or under 11 weeks pregnancy gestation on initial intake.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!